ABL1 and acute lymphoblastic leukemia: All patients receive dasatinib with the exception of those with ABL-class ALL harboring PDGFRB treated with imatinib, based upon recent robust data demonstrating differential TKI sensitivity amongst specific ABL-class fusion subgroups [98].